Viropro acquires biotech production facility

US-based biopharmaceutical company Viropro has acquired a Cambridge biotech facility in a deal worth $21 million (£13 million).

The deal includes a 5,000 square-metre facility in Malaysia for the production of mammalian cells, which, along with the Cambridge site, recently underwent redevelopment.

The Cambridge laboratory is responsible for research and development of bioprocesses, a procedure using complete living cells, or their components, to obtain products.

Rajiv Datar, president and CEO of Viropro comments: ‘With this acquisition, Viropro has taken the first step towards creating a global biotech contract services business.’

Kim Tan, chairman of Alpha Biologics says: ‘We look forward to working closely with Viropro and its other subsidiaries towards the realisation of a common mission, which is to make biotech drugs for clients, efficiently and economically.’

Nick Britton

Nick Britton

Nick was the Managing Editor for when it was owned by Vitesse Media, before moving on to become Head of Investment Group and Editor at What Investment and thence to Head of Intermediary...